---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-037353"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:14:48.493913+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zai Lab Q3 revenue $69.2M (+22% YoY); launches VYVGART in China, net loss narrows

## Summary
- Product revenue $69.2M, up 22% YoY; VYVGART contributed $4.9M since September launch.
- Net loss $69.2M vs $161.2M in Q3 2022; R&D expenses fell to $58.8M from $99.5M.
- Cash $822.2M at Sept 30, down from $876.4M at June 30, 2023.
- Terminated ZL-1211 (Claudin18.2) development; appointed Dr. Robert Brown as CMO, Oncology.
- Expects at least seven product launches in 2-3 years; multiple NDAs under review (repotrectinib, odronextamab).

## SEC filing metadata
- accession: 0001628280-23-037353
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000162828023037353/0001628280-23-037353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000162828023037353/zlab-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-037353
- JSON: https://secwatch.observer/filing/0001628280-23-037353.json
- Plain text: https://secwatch.observer/filing/0001628280-23-037353.txt

## Key facts
- Earnings Releases
  Zai Lab Ltd reported third quarter 2023 results: revenue $69.2 million, net income $69.2 million, EPS $0.07.
  - Period: third quarter 2023
  - Revenue: $69.2 million
  - Net income: $69.2 million
  - EPS: $0.07
  - Result: reported results
  source text: Third Quarter 2023 Financial Results • Product revenues were $69.2 million for the third quarter of 2023, compared to $57.0 million for the same period in 2022, representing 22% y-o-y growth and 27% y-o-y growth at CER. This increase was primarily driven by increased sales volumes, the launch of VYVGART, and decreased negative effects from the COVID-19 pandemic . Our revenue growth was slowed by the effects on hospital and physician practices from the recent industry-wide anti-corruption enforcement efforts in China. Product revenues in the third quarter of 2023, compared to the same period in 2022, included: – $41.6 million for ZEJULA, which increased from $39.2 million, as ZEJULA, which is in its third year on the NRDL, continued to be the leading PARP inhibitor in hospital sales for ovarian cancer in China; – $11.6 million for Optune, which increased from $10.7 million, supported by increased patient access to this product in the private-pay market; – $5.7 million for QINLOCK, which
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704292/000162828023037353/0001628280-23-037353-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.